The NM_000023.4: c.269A>G variant in SGCA is a missense variant predicted to cause substitution of tyrosine by cysteine at amino acid 90, p.(Tyr90Cys). This variant has been detected in at least three individuals with limb-girdle muscular dystrophy (PMID: 12566530; LOVD Individual #00133346; GRASP-LGMD Consortium internal data communication). Two patients, one from a consanguineous family, were homozygous for the variant (0.75 pts; PMID: 12566530, LOVD Individual #00133346). The third patient had the likely pathogenic variant c.614C>A p.(Pro205His) in unconfirmed phase (0.25 pts, GRASP-LGMD Consortium internal data communication) (PM3). At least one patient homozygous for this variant displayed progressive limb girdle muscle weakness and absent alpha-sarcoglycan protein expression, which is highly specific for SGCA-related LGMD (PP4_Strong; PMID: 12566530). The variant also segregated with autosomal recessive limb girdle muscular dystrophy in one affected family member (PP1; PMID: 12566530). The upper bound of the 95% confidence interval (95% CI) of the Grpmax variant allele frequency in gnomAD v4.1.1 is 0.0000175 (13/1179600 European (non-Finnish) alleles), which is lower than the LGMD VCEP threshold (<0.00009) for PM2_Supporting, and therefore meets this criterion. The computational predictor REVEL gives a score of 0.962, which is above the threshold of 0.7, evidence that correlates with impact to SGCA function (PP3). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive limb girdle muscular dystrophy based on the ACMG/AMP criteria applied, as specified by the ClinGen LGMD VCEP (LGMD VCEP specifications version 2.0.0; 05/01/2026): PM3, PP4_Strong, PP1, PM2_Supporting, PS3_Moderate, PP3.